Rexahn Completes Public Company Merger

Rexahn Completes Public Company Merger

Rexahn now a publicly traded company

(May 16, 2005) Rexahn, Corp, a biopharmaceutical company focusing on

signal inhibitor therapies for cancer and central nervous system diseases, announced today

the completion of a merger transaction with Corporate Roadshow.Com Inc. (CPRD.OB), a

publicly-held company based in New York. The combined corporation is named Rexahn

Pharmaceuticals, Inc. and its shares will trade on the OTC Bulletin Board beginning today

under the symbol RXHN.OB. The merger was effective as of the close of business on May 13,

Completing this merger

represents an important business milestone for Rexahn, said Dr. Chang Ahn, Chairman

and CEO of Rexahn. As a public company, we now have a wider range of financing

strategies available to us to capitalize on future investment opportunities to strengthen

the company s financial position, provide the necessary resources to implement our

R&D programs and pursue our commercialization strategy.

Rexahn s lead drug candidate

RX-0201 is currently in Phase I clinical trials at Georgetown University s Lombardi

Cancer Center. RX-0201 is a first-in-class signal inhibitor that directly inhibits the

production of Akt, a protein kinase that plays a key role in cancer progression. A

potentially less toxic therapeutic approach to cancer treatment, RX-0201 inhibits

proliferation of cancer cells, in part, through promoting cell death (apoptosis) and

blocks the growth of tumors in animal models. Orphan drug designation has been granted to

RX-0201 for the treatment of ovarian cancer, renal cell carcinoma, glioblastoma, stomach

cancer, and pancreatic cancer.

In addition, other oncology drug

candidates being prepared for clinical development include RX-0183 (AP-1/Akt inhibitor),

RX-5315 (G2/M inhibitor), RX-0047 (HIF inhibitor) and RX-3117 (a new nucleoside). Leading

the way in the development program for Rexahn s neurology drug pipeline is RX-10100,

a drug candidate for the treatment of anxiety and depression.

In connection with the merger,

Rexahn s officers and directors replaced those of Corporate Roadshow and Corporate

Roadshow ceased all of its existing operations and adopted Rexahn s business plan.

In the merger, approximately 38

million shares of Rexahn Pharmaceuticals common stock were issued to the holders of Rexahn

common stock. The former Rexahn stockholders now own approximately 92% of Rexahn

Pharmaceuticals common stock

and the stockholders of

Corporate Roadshow now own approximately 8% of Rexahn Pharmaceuticals common stock.

Rexahn Pharmaceuticals, Inc. is a

development stage biopharmaceutical company dedicated to leveraging its unique discovery

platforms, in-house scientific expertise and drug development know-how to advance next

generation therapeutics for oncology and central nervous system diseases with unmet

medical needs. The company is headquartered in Rockville, MD and additional information is

available at http://www.rexahn.com.

This press release contains

statements (including projections and business trends) that are forward-looking

statements. Rexahn s actual results may differ materially from the anticipated

results and expectations expressed in these forward-looking statements as a result of

certain risks and uncertainties, including, Rexahn s lack of profitability, its

auditor s going concern qualification and the need for additional capital to operate

its business to develop its product candidates; the risk that Rexahn s development

efforts relating to its product candidates may not be successful; the possibility of being

unable to obtain regulatory approval of Rexahn s product candidates; the risk that

the results of clinical trials may not be completed on time or support Rexahn s

claims; demand for and market acceptance of Rexahn s drug candidates; Rexahn s

reliance on third party researchers and manufacturers to develop its product candidates;

Rexahn s ability to develop and obtain protection of its intellectual property; and

other risk factors set forth from time to time in our filings with the Securities and

Exchange Commission. These forward-looking statements are made as of the date hereof,

Rexahn assumes no obligation to update these forward-looking statements, whether as a

result of new information, future events or otherwise.